Alice Pedersen

Alice Pedersen

Auto-generated profile, based on publicly available information

Alice Pedersen

Department of Biomedicine, Aarhus University, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2025 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
BZBao-Cun Zhang
Bao-Cun Zhang
APAlice Pedersen
Alice Pedersen
LRLine Reinert
Line Reinert
YLYing Li
Ying Li
RNRyo Narita
Ryo Narita
SPSøren R. Paludan
Søren R. Paludan

27 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LHLili Hu
Lili Hu
Renée Marije Van Der SluisRenée Marije Van Der Sluis
Renée Marije Van Der Sluis
KCKennith Brian Castelino
Kennith Brian Castelino
BZBao-Cun Zhang
Bao-Cun Zhang
ARAndreas Ronit
Andreas Ronit
TMTrine Mogensen
Trine Mogensen
The clinical outcome of SARS-CoV-2 infection spans from asymptomatic viral elimination to lethal COVID-19 pneumonia, which is due to type I interferon (IFN) deficiency in at least 15–20% of cases. We report two unrelated male patients with critical COVID-19 who are heterozygous for rare deleterious variants in RB1CC1, encoding the autophagy-related FIP200 protein. Airway epithelial cells genetically deprived of FIP200 or cell lines expressing the RB1CC1/FIP200 patient variants exhibit elevated SARS-CoV-2 replication and impaired autophagic flux. The antiviral function of FIP200 is independent of canonical autophagy and type I IFN, but involves the selective autophagy receptor NDP52. We identify a non-canonical function of FIP200 in a novel lysosomal degradation pathway, in which SARS-CoV-2 virions are targeted to single-membrane compartments for degradation of viral RNA in LC3B-positive acidified vesicles. This pathway is impaired in FIP200-deficient cells and in cells expressing FIP200 patient haplotypes. Collectively, we describe a cell-autonomous anti-SARS-CoV-2 restriction pathway, dependent on FIP200 and NDP52, and independent of canonical autophagy and type I IFN, which can underlie critical COVID-19 pneumonia.